The morality of Valeant’s operating model is often brought into question from an emotional perspective but here’s a counter argument. Pharmaceutical companies invest in R&D for a return which (sometimes) is through selling the drug on the market. Valeant is just offering another channel through which pharmaceutical companies can make that return: having their drug acquired. True, if EVERY pharmaceutical company did what Valeant did, it would be a disaster. But that doesn’t mean there isn’t a space for Valeant. As for the price increases, Billy Ackman swears the company is just as strong without them.
Haha this is awesome. I love Yakult and Yakult ladies is ingenious!
Wow, that’s crazy how long the software refresh cycle is! I do wonder if there’s room in Guidewire’s operating model to become even more efficient, given they are currently in a fairly protected position and arguably have little incentive to slim down…
TOM process improvements in luxury goods? I had no idea! This is a really interesting read. It does actually beg the question: how much automation would consumers accept and still consider a product luxury?
A common message from VCs is that great ideas are a dime a dozen but great teams are hard to come by. How does Rocket Internet deal with this issue? It seems like they are just transplanting good ideas but do their teams really have the conviction to execute? (Especially since Rocket Internet owns the equity…?)